Zentalis Pharmaceuticals Reports Improved Net Loss of $26.7 Million in Q3 2025

Zentalis Pharmaceuticals, Inc. reported a net loss of $26.7 million for the third quarter of 2025, a significant improvement compared to a net loss of $40.2 million in the same period last year. For the nine months ending September 30, 2025, the company recorded a net loss of $101.8 million, down from $118.4 million in the prior year. The reduction in losses is attributed to a decrease in operating expenses, which totaled $33.7 million for the quarter, down from $51.4 million in Q3 2024. This decline was primarily driven by lower research and development costs, which fell to $23.0 million from $36.8 million year-over-year, reflecting the company's strategic restructuring efforts.

Zentalis has not generated any revenue from product sales, with total operating expenses for the nine months ending September 30, 2025, amounting to $115.4 million, a decrease from $181.9 million in the same period of 2024. The company’s restructuring, which included a workforce reduction of approximately 40%, resulted in $7.8 million in restructuring expenses. The company also reported no license revenue for the nine months ended September 30, 2025, compared to $40.6 million in the previous year, which was derived from a licensing agreement with Immunome.

In terms of operational developments, Zentalis is focused on advancing its lead product candidate, azenosertib, an investigational WEE1 inhibitor for treating Cyclin E1-positive platinum-resistant ovarian cancer. The company is currently conducting the DENALI Part 2 clinical trial, which aims to enroll approximately 100 patients. The FDA has granted Fast Track Designation for azenosertib, and the company anticipates disclosing topline data from this trial by the end of 2026. As of September 30, 2025, Zentalis had cash, cash equivalents, and marketable securities totaling $280.7 million, which it believes will fund operations into late 2027.

Zentalis has also engaged in strategic collaborations, including a license agreement with Immunome for a preclinical ROR1 antibody-drug conjugate, which resulted in cash and stock proceeds totaling $20 million. The company divested shares of Immunome common stock, generating additional cash inflow. Despite these efforts, Zentalis acknowledges the need for substantial additional capital to support ongoing operations and future growth, particularly as it continues to develop azenosertib and other potential product candidates. The company remains cautious about the impact of external factors, including regulatory delays and market conditions, on its business outlook.